Menu
Search
|

Menu

Close
X

Interpace Diagnostics Group Inc IDXG.OQ (NASDAQ Stock Exchange Capital Market)

1.36 USD
+0.00 (+0.00%)
As of Oct 19
chart
Previous Close 1.36
Open 1.36
Volume 30,924
3m Avg Volume 77,387
Today’s High 1.40
Today’s Low 1.35
52 Week High 1.78
52 Week Low 0.77
Shares Outstanding (mil) 22.16
Market Capitalization (mil) 35.91
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
10
FY17
16
FY16
13
FY15
43
EPS (USD)
FY18
-0.180
FY17
-0.561
FY16
-4.754
FY15
-12.844
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
24.52
Price to Sales (TTM)
vs sector
2.61
46.48
Price to Book (MRQ)
vs sector
0.90
2.68
Price to Cash Flow (TTM)
vs sector
--
16.11
Total Debt to Equity (MRQ)
vs sector
0.00
91.06
LT Debt to Equity (MRQ)
vs sector
0.00
69.71
Return on Investment (TTM)
vs sector
-13.70
7.50
Return on Equity (TTM)
vs sector
-24.97
12.39

EXECUTIVE LEADERSHIP

Stephen Sullivan
Chairman of the Board, Since 2016
Salary: --
Bonus: --
Jack Stover
President, Chief Executive Officer, Director, Since 2016
Salary: $8,065.00
Bonus: --
James Early
Chief Financial Officer, Since 2018
Salary: $116,519.00
Bonus: --
Thomas Freeburg
Chief Accounting Officer and Principal Accounting Officer, Since 2018
Salary: --
Bonus: --
Felice Schnoll-Sussman
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Industrials
Industry: Business Support Services
Address:

Morris Corporate Center 1
, Building C, 300 Interpace Park
PARSIPPANY   NJ   07054

Phone: +1412.2246100

Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

SPONSORED STORIES